Dynavax to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) announces that CEO Ryan Spencer will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021.

The on-demand presentation will be accessible starting September 13, 2021, at 7:00 a.m. E.T. via the Company's Investors section. Dynavax focuses on the development and commercialization of vaccines, including its first product, HEPLISAV-B®, for Hepatitis B prevention.

EMERYVILLE, Calif., Sept. 9, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

The on demand presentation will be available, beginning Monday, September 13, 2021 at 7:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and Europe for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt
narndt@dynavax.com 
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301372861.html

SOURCE Dynavax Technologies

FAQ

When is Dynavax presenting at the H.C. Wainwright Conference?

Dynavax will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

What time can I access Dynavax's presentation?

The on-demand presentation from Dynavax will be available starting September 13, 2021, at 7:00 a.m. E.T.

What is the focus of Dynavax Technologies Corporation?

Dynavax is a biopharmaceutical company focused on developing and commercializing vaccines, including HEPLISAV-B® for Hepatitis B.

Where can I find Dynavax's presentation online?

Dynavax's presentation can be accessed through the 'Events & Presentations' page in the Investors section of their website.

What is HEPLISAV-B®?

HEPLISAV-B® is a Hepatitis B Vaccine developed by Dynavax and approved for use in adults aged 18 years and older.